Synthesis of new ibuprofen derivatives with their in silico and in vitro cyclooxygenase-2 inhibitions


GÜNDOĞDU HIZLIATEŞ C., ALYÜRÜK H., Gocmenturk M., Ergun Y., ÇAVAŞ L.

BIOORGANIC CHEMISTRY, cilt.52, ss.8-15, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.bioorg.2013.10.002
  • Dergi Adı: BIOORGANIC CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.8-15
  • Anahtar Kelimeler: Cyclooxygenase-2, Ibuprofen, Molecular docking, Molecular modeling, Selective inhibitor, SELECTIVE COX-2 INHIBITORS, BIOLOGICAL EVALUATION, ANTIINFLAMMATORY ACTIVITY, SCORING FUNCTIONS, DOCKING, DESIGN, PHARMACOPHORE, ANALOGS, ESTER, VALDECOXIB
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Cyclooxygenase-2 (COX-2) is one of the important targets for treatment of inflammation related diseases. In the literature, most of drug candidates are first synthesized and then their COX-2 inhibitory activities are tested by in vitro and in vivo experiments. However, synthesis of dozens of drug analogues without any interpretations on their inhibitory activity can result in loss of time and chemicals. Therefore, synthetic drug designs with molecular modeling are of importance to synthesize selective drug candidates against inflammatory diseases. The synthesis of the novel ibuprofen derivatives through their in silico and in vitro COX-2 inhibitory activities were investigated in the present study. Starting from ibuprofen, ibuprofen amide and ibuprofen acyl hydrazone derivatives were synthesized. According to the results of the in silico molecular docking and in vitro enzyme inhibition studies, the synthesized novel ibuprofen derivatives have selective COX-2 inhibition, and molecule 3a and 3c were showed higher inhibition compared to ibuprofen. In conclusion, the newly synthesized ibuprofen derivatives can be used in model in vivo studies. (C) 2013 Elsevier Inc. All rights reserved.